Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04960202 · ClinicalTrials.gov registry record · Phase 2

EPIC-HR: Study of Oral PF-07321332/Ritonavir Compared With Placebo in Nonhospitalized High Risk Adults With COVID-19

A Phase 2 study of COVID-19, sponsored by Pfizer.

Completed
Registry status
Phase 2
Development phase
2,091
Enrollment target
20
Study locations

NCT04960202 is a Phase 2 study of COVID-19 that has completed, run by Pfizer. The registered enrollment target is 2,091 participants, below the 55,204-participant average among 203 other COVID-19 trials with a reported enrollment target (96% lower). The trial reports 20 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04960202, a Phase 2 study of COVID-19, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 2
Development phase
2,091 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to determine whether PF-07321332/ritonavir is safe and effective for the treatment of adults who are ill with COVID-19 and do not need to be in the hospital, but are at an increased risk of developing severe illness. Throughout the study period, provision will be made to allow study visits to be conducted at a participant's home or another non-clinic location if available. The total study duration is up to 24 weeks.

Conditions Studied

COVID-19

Interventions

  • DRUG Placebo
  • DRUG Ritonavir
  • DRUG PF-07321332

Study Locations (20)

Florida

  • Xera Med Research - Boca Raton
  • MOORE Clinical Research, Inc. - Brandon
  • Innovative Research of West Florida, Inc. - Clearwater
  • Herco Medical and Research Center Inc - Coral Gables
  • Advance Clinical Research Group - Cutler Bay
  • Beautiful Minds Clinical Research Center - Cutler Bay
  • Qway Research - Hialeah
  • Eastern Research Inc - Hialeah
  • Inpatient Research Clinic - Hialeah

California

  • Hope Clinical Research - Canoga Park
  • Ascada Research - Fullerton
  • Atella Clinical Research LLC. - La Palma
  • Ark Clinical Research - Long Beach
  • American Institute of Research - Los Angeles
  • South Bay Clinical Research Institute - Redondo Beach
  • Hope Clinical Research (COVID Satellite Site) - West Hills

Arizona

  • The Institute for Liver Health dba Arizona Clinical Trials - Mesa
  • The Institute for Liver Health dba Arizona Clinical Trials - Tucson

Alabama

  • Cahaba Research Inc - Pelham

Colorado

  • Future Innovative Treatments, LLC - Colorado Springs

Trial Details

FieldValue
Enrollment Target 2,091 participants
Start Date 2021-07-16
Est. Completion 2022-04-25
Phase Phase 2

Sponsor

Pfizer

1,845 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04960202

The ClinicalTrials.gov registry entry for NCT04960202 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 2,091 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 55,204-participant average among 203 other COVID-19 trials with a reported enrollment target (96% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with COVID-19 appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT04960202 reports 20 study locations spanning 5 distinct geographic areas - top geographies include Florida, California, Arizona.

Frequently Asked Questions

What is clinical trial NCT04960202 about?

NCT04960202 is a clinical study titled "EPIC-HR: Study of Oral PF-07321332/Ritonavir Compared With Placebo in Nonhospitalized High Risk Adults With COVID-19". The purpose of this study is to determine whether PF-07321332/ritonavir is safe and effective for the treatment of adults who are ill with COVID-19 and do not need to be in the hospital, but are at an increased risk of developing severe illness. Throughout the study period, provision will be made to...

What is the current status of trial NCT04960202?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 2,091 participants. The study started on 2021-07-16. Estimated completion is 2022-04-25.

What conditions does trial NCT04960202 study?

This clinical trial studies the following conditions: COVID-19.

What interventions are being tested in trial NCT04960202?

The interventions under investigation include: Placebo (DRUG), Ritonavir (DRUG), PF-07321332 (DRUG).

Who is sponsoring clinical trial NCT04960202?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04960202 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for COVID-19

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

COVID-19

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.